You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 418 A phase 1, dose escalation and dose expansion study of SQZ PBMC HPV as monotherapy and in combination with atezolizumab in HLA-A*02+ Patients with HPV16+ recurrent, or metastatic solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
418 A phase 1, dose escalation and dose expansion study of SQZ PBMC HPV as monotherapy and in combination with atezolizumab in HLA-A*02+ Patients with HPV16+ recurrent, or metastatic solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020158010
Dec 20204406
Jan 202154010
Feb 202162012
Mar 202182010
Apr 202136011
May 20217014
Jun 20210012
Jul 20210012
Aug 20210011
Sep 2021007
Oct 202146027
Nov 202143034
Dec 20215206
Jan 20224405
Feb 20222803
Mar 20223400
Apr 202278011
May 20226003
Jun 20227206
Jul 20226006
Aug 202215408
Sep 20223203
Oct 20223801
Nov 20225006
Dec 20227405
Jan 20236405
Feb 20235000
Mar 20234004
Apr 202338010
May 20234204
Jun 20234003
Jul 20235804
Aug 20233605
Sep 20233804
Oct 20235404
Nov 20234003
Dec 20235800
Jan 20242805
Feb 20242402
Mar 20241402
Apr 20241802
May 20242002
Jun 20242104
Jul 20243203
Aug 20244606
Sep 20243905
Oct 20243208
Nov 20242602
Dec 202434010
Jan 20254009
Feb 2025008
Mar 2025004
Apr 20250015
May 2025002
Jun 2025106
Total22410380